BioSpace News Archive

Supernus Pharmaceuticals, Inc. announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat, as well as host investor meetings, at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 9:50 a.m. ET.

Oncternal Therapeutics, Inc. announced that it has granted an inducement award to one new employee, Yelena Tsabur, who joined Oncternal as Associate Clinical Trial Manager.

Owens & Minor, Inc. (NYSE: OMI) announced today that executive leadership will participate in a fireside chat at the upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference.

RefleXion Medical, Inc., a therapeutic oncology company, announced the installation of its RefleXion® X1 platform at Smilow Cancer Hospital, part of Yale New Haven Health, Connecticut’s largest healthcare system.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM (Nasdaq: SOPH) that will bring together its QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform.

Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Alessa Therapeutics announced their collaboration for developing a new oncology drug product leveraging Alessa’s expertise on sustained localized drug delivery and the Celanese VitalDose® EVA drug delivery platform.

CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced the close of a $200 million oversubscribed and upsized Series A financing.

Praetego Inc. is pleased to announce a $0.3M STTR award from the National Eye Institute.

Immune Therapeutics, Inc. announced the majority of its stockholders have approved a name change to Biostax Corp. as detailed in the Form PRE 14C that was filed with the SEC yesterday, February 28, 2023.

Pressure BioSciences, Inc., a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, announced that the Company’s largest shareholder has exchanged over $10 million of senior secured debt into unsecured preferred stock.